Audentes Therapeutics, Inc. (NASDAQ:BOLD) – Stock analysts at William Blair issued their Q1 2018 EPS estimates for shares of Audentes Therapeutics in a research report issued on Friday. William Blair analyst R. Prasad expects that the biotechnology company will post earnings of ($0.82) per share for the quarter. William Blair currently has a “Outperform” rating and a $35.00 price objective on the stock. William Blair also issued estimates for Audentes Therapeutics’ Q2 2018 earnings at ($0.85) EPS, Q3 2018 earnings at ($0.87) EPS and Q4 2018 earnings at ($0.90) EPS.

Several other equities analysts have also weighed in on the company. ValuEngine lowered Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, October 13th. Raymond James Financial, Inc. began coverage on Audentes Therapeutics in a report on Thursday, October 12th. They set a “market perform” rating on the stock. Zacks Investment Research lowered Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Bank of America Corporation restated a “buy” rating and set a $33.00 target price (up from $23.00) on shares of Audentes Therapeutics in a report on Friday, September 22nd. Finally, Evercore ISI began coverage on Audentes Therapeutics in a report on Wednesday, August 16th. They set an “outperform” rating and a $23.00 target price on the stock. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $25.71.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/10/23/brokers-offer-predictions-for-audentes-therapeutics-inc-s-q1-2018-earnings-bold.html.

Shares of Audentes Therapeutics (BOLD) opened at 24.98 on Monday. Audentes Therapeutics has a 52 week low of $13.13 and a 52 week high of $33.43. The firm’s market capitalization is $694.04 million. The firm’s 50-day moving average price is $26.58 and its 200 day moving average price is $26.58.

Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($0.10).

In other news, VP Suyash Prasad sold 8,000 shares of Audentes Therapeutics stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $21.44, for a total value of $171,520.00. Following the transaction, the vice president now directly owns 8,000 shares in the company, valued at $171,520. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Matthew R. Patterson sold 25,000 shares of Audentes Therapeutics stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $27.92, for a total value of $698,000.00. The disclosure for this sale can be found here. Insiders sold 766,500 shares of company stock worth $21,443,730 over the last quarter. 47.30% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the company. Sphera Funds Management LTD. bought a new position in shares of Audentes Therapeutics in the second quarter worth about $2,870,000. Wells Fargo & Company MN increased its stake in shares of Audentes Therapeutics by 278.5% in the first quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 5,700 shares during the period. Rhumbline Advisers bought a new position in shares of Audentes Therapeutics in the second quarter worth about $252,000. Alliancebernstein L.P. increased its stake in shares of Audentes Therapeutics by 31.5% in the second quarter. Alliancebernstein L.P. now owns 640,654 shares of the biotechnology company’s stock worth $12,256,000 after purchasing an additional 153,617 shares during the period. Finally, Ardsley Advisory Partners increased its stake in shares of Audentes Therapeutics by 59.7% in the second quarter. Ardsley Advisory Partners now owns 20,072 shares of the biotechnology company’s stock worth $384,000 after purchasing an additional 7,500 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Earnings History and Estimates for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.